Neurogene (NGNE)
Builds a single gene therapy for Rett syndrome using a proprietary expression-control platform.
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 109.77% | 17.35M shares | |
|---|---|---|---|
| 117 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.80% | 127.0K shares | |
| 3 holders · as of Jul 7, 2026 | |||
| Adds to | 110.57% | ||
15.80M company shares as of Sep 12, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (20.01M in the company's Sep 22, 2026 report, 15.80M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 110.57%; nothing is left for Other.
13F, as of Jun 30, 2026
117 holders · 17.35M shares · 23 new positions · 62 increased · 32 reduced · 6 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Samsara Biocapital, LLC | 1.72M | 10.87% | 0 | Aug 14, 2026 |
| Casdin Capital, LLC | 1.55M | 9.78% | +125.0K | Aug 14, 2026 |
| Redmile Group, LLC | 1.41M | 8.94% | −47.4K | Aug 14, 2026 |
| RTW Investments, LP | 1.36M | 8.62% | 0 | Aug 14, 2026 |
| Ecor1 Capital, LLC | 1.27M | 8.05% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 1.06M | 6.70% | +52.9K | Aug 7, 2026 |
| Baker Bros. Advisors LP | 991.7K | 6.28% | 0 | Aug 14, 2026 |
| Balyasny Asset Management L.P. | 818.7K | 5.18% | +100.3K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| RTW Investments, LP | 9.99% | 1.50M | 13G | Feb 14, 2025 |
| Redmile Group, LLC | 9.90% | 1.56M | 13G | Feb 17, 2026 |
| EcoR1 Capital, LLC | 9.90% | 1.44M | 13G | Nov 14, 2025 |
| Casdin Capital, LLC | 8.70% | 1.30M | 13G | Feb 14, 2025 |
| Baker Bros. Advisors LP | 7.00% | 991.7K | 13G | Aug 14, 2025 |
| Eli Casdinincl. Casdin Capital, LLC, Casdin Partners Master Fund, L.P. +1 more | 6.90% | 1.02M | 13G | Nov 8, 2024 |
| BlackRock, Inc. | 6.80% | 1.01M | 13G | Apr 23, 2025 |
| FMR LLCincl. Abigail P. Johnson | 5.63% | 731.8K | Nov 12, 2024 | |
| Capital Master LPincl. Capital LP | 5.40% | 800.0K | 13G | Dec 11, 2024 |
| Balyasny Asset Management L.P. | 5.18% | 818.7K | 13G | Aug 14, 2026 |
| Trails Edge Capital Partners, LP | 5.10% | 785.0K | 13G | Dec 15, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 7, 2026 | Christine Mikail Cvijicdirector, officer: President and CFO | Sale | 4,200 | $36.13 | 84,040 |
| Jul 6, 2026 | Christine Mikail Cvijicdirector, officer: President and CFO | Sale | 600 | $36.02 | 88,240 |
| Jul 2, 2026 | Christine Mikail Cvijicdirector, officer: President and CFO | Sale · 2 lots | 4,061 | $34.82 | 88,840 |
| Jul 1, 2026 | Christine Mikail Cvijicdirector, officer: President and CFO | Sale | 739 | $34.06 | 92,901 |
| May 6, 2026 | Christine Mikail Cvijicdirector, officer: President and CFO | Sale · 2 lots | 9,600 | $31.25 | 93,640 |
| Mar 26, 2026 | Julie Jordanofficer: Chief Medical Officer | Sale | 828 | $21.89 | 12,472 |
| Mar 26, 2026 | Rachel McMinndirector, officer: Chief Executive Officer | Sale | 3,352 | $22.07 | 1,344,307 |
| Mar 26, 2026 | Christine Mikail Cvijicofficer: President and CFO | Sale | 2,558 | $21.62 | 103,240 |
| Mar 13, 2026 | Christine Mikail Cvijicofficer: President and CFO | Sale · 3 lots | 4,045 | $20.81 | 105,798 |
| Mar 13, 2026 | Stuart Cobbofficer: Chief Scientific Officer | Sale · 3 lots | 6,797 | $20.81 | 30,497 |
House and Senate disclosures
Not reported.